Skip to main content
Top
Published in: Medical Oncology 4/2014

01-04-2014 | Original Paper

Association between polymorphisms at promoters of XRCC5 and XRCC6 genes and risk of breast cancer

Authors: Mehrdad Rajaei, Iraj Saadat, Shahpour Omidvari, Mostafa Saadat

Published in: Medical Oncology | Issue 4/2014

Login to get access

Abstract

Variation in DNA repair genes is one of the mechanisms that may lead to variation in DNA repair capacity. Ku, a heterodimeric DNA-binding complex, is directly involved in repair of DNA double-strand breaks. Ku consists of two subunits, Ku70 and Ku80, which are encoded by the XRCC6 and XRCC5 genes, respectively. In the present study, we investigated whether common genetic variant in variable number of tandem repeats (VNTR) XRCC5 and T-991C XRCC6 was associated with an altered risk of breast cancer. The present study included 407 females with breast cancer and 395 age frequency-matched controls which were randomly selected from the healthy female blood donors. The XRCC5 and XRCC6 polymorphisms were determined using PCR-based methods. For XRCC5 polymorphism, in comparison with the 1R/1R genotype, the 0R/0R genotype increased breast cancer risk (OR 9.55, 95 %CI 1.19–76.64, P = 0.034). The 1R/3R genotype compared with 1R/1R genotype decreased the risk of breast cancer (Fisher’s exact test P = 0.015). There was no association between T-991C polymorphism of XRCC6 and breast cancer risk. Mean of age at diagnosis of breast cancer for 0, 1, 2, 3, and >4 repeat in XRCC5 were 39.2, 41.9, 44.3, 45.8, and 47.3 years, respectively. The Kaplan–Meier survival analysis revealed that the number of repeat was associated with age at diagnosis of breast cancer (log rank statistic = 13.90, df = 4, P = 0.008). The findings of the present study revealed that either breast cancer risk or age at diagnosis of breast cancer was associated with the VNTR polymorphism at promoter region of XRCC5.
Literature
3.
go back to reference Mohrenweiser HW, Jones IM. Variation in DNA repair is a factor in cancer susceptibility: a paradigm for the promises and perils of individual and population risk estimation? Mutat Res. 1998;400:15–24.PubMedCrossRef Mohrenweiser HW, Jones IM. Variation in DNA repair is a factor in cancer susceptibility: a paradigm for the promises and perils of individual and population risk estimation? Mutat Res. 1998;400:15–24.PubMedCrossRef
4.
go back to reference Fu YP, Yu JC, Cheng TC, Lou MA, Hsu GC, Wu CY, Chen ST, Wu HS, Wu PE, Shen CY. Breast cancer risk associated with genotypic polymorphism of the nonhomologous end-joining genes: a multigenic study on cancer susceptibility. Cancer Res. 2003;63:2440–6.PubMed Fu YP, Yu JC, Cheng TC, Lou MA, Hsu GC, Wu CY, Chen ST, Wu HS, Wu PE, Shen CY. Breast cancer risk associated with genotypic polymorphism of the nonhomologous end-joining genes: a multigenic study on cancer susceptibility. Cancer Res. 2003;63:2440–6.PubMed
5.
go back to reference Dobbs TA, Tainer JA, Less-Miller SP. A structural model for regulation of NHEJ by DNA-PKcs autophosphorylation. DNA Repair. 2010;10:1307–14.CrossRef Dobbs TA, Tainer JA, Less-Miller SP. A structural model for regulation of NHEJ by DNA-PKcs autophosphorylation. DNA Repair. 2010;10:1307–14.CrossRef
6.
go back to reference Park SJ, Ciccone SL, Freie B, Kurimasa A, Chen DJ, Li GC, Clapp DW, Lee SH. A positive role for the Ku complex in DNA replication following strand break damage in mammals. J Biol Chem. 2004;279:6046–55.PubMedCrossRef Park SJ, Ciccone SL, Freie B, Kurimasa A, Chen DJ, Li GC, Clapp DW, Lee SH. A positive role for the Ku complex in DNA replication following strand break damage in mammals. J Biol Chem. 2004;279:6046–55.PubMedCrossRef
7.
go back to reference Kuschel B, Auranen A, McBride S, Novik KL, Antoniou A, Lipscombe JM, Day NE, Easton DF, Ponder BA, Pharoah PD, Dunning A. Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet. 2002;11:1399–407.PubMedCrossRef Kuschel B, Auranen A, McBride S, Novik KL, Antoniou A, Lipscombe JM, Day NE, Easton DF, Ponder BA, Pharoah PD, Dunning A. Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet. 2002;11:1399–407.PubMedCrossRef
8.
go back to reference Rajaei M, Saadat I, Saadat M. Introducing a novel allele for the polymorphism of variable number of tandem repeats in the promoter region of XRCC5. Biochem Biophys Res Commun. 2012;427:503–5.PubMedCrossRef Rajaei M, Saadat I, Saadat M. Introducing a novel allele for the polymorphism of variable number of tandem repeats in the promoter region of XRCC5. Biochem Biophys Res Commun. 2012;427:503–5.PubMedCrossRef
9.
go back to reference Rajaei M, Saadat I, Saadat M. The novel allele (3R) of the VNTR polymorphism in the XRCC5 promoter region dramatically decreases the gene expression. Biochem Biophys Res Commun. 2013;430:640–1.PubMedCrossRef Rajaei M, Saadat I, Saadat M. The novel allele (3R) of the VNTR polymorphism in the XRCC5 promoter region dramatically decreases the gene expression. Biochem Biophys Res Commun. 2013;430:640–1.PubMedCrossRef
10.
go back to reference Wang S, Wang M, Yin S, Fu G, Li C, Chen R, Li A, Zhou J, Zhang Z, Liu Q. A novel variable number of tandem repeats (VNTR) polymorphism containing Sp1 binding elements in the promoter of XRCC5 is a risk factor for human bladder cancer. Mutat Res. 2008;638:26–36.PubMedCrossRef Wang S, Wang M, Yin S, Fu G, Li C, Chen R, Li A, Zhou J, Zhang Z, Liu Q. A novel variable number of tandem repeats (VNTR) polymorphism containing Sp1 binding elements in the promoter of XRCC5 is a risk factor for human bladder cancer. Mutat Res. 2008;638:26–36.PubMedCrossRef
11.
go back to reference Bau DT, Tseng HC, Wang CH, Chiu CF, Hua CH, Wu CN, Liang SY, Wang CL, Tsai CW, Tsai MH. Oral cancer and genetic polymorphism of DNA double strand break gene Ku70 in Taiwan. Oral Oncol. 2008;44:1047–51.PubMedCrossRef Bau DT, Tseng HC, Wang CH, Chiu CF, Hua CH, Wu CN, Liang SY, Wang CL, Tsai CW, Tsai MH. Oral cancer and genetic polymorphism of DNA double strand break gene Ku70 in Taiwan. Oral Oncol. 2008;44:1047–51.PubMedCrossRef
12.
go back to reference Yang MD, Wang HC, Chang WS, Tsai CW, Bau DT. Genetic polymorphisms of DNA double strand break gene Ku70 and gastric cancer in Taiwan. BMC Cancer. 2011;11:174–8.PubMedCentralPubMedCrossRef Yang MD, Wang HC, Chang WS, Tsai CW, Bau DT. Genetic polymorphisms of DNA double strand break gene Ku70 and gastric cancer in Taiwan. BMC Cancer. 2011;11:174–8.PubMedCentralPubMedCrossRef
13.
go back to reference Hsia TC, Liu CJ, Chu CC, Hang LW, Chang WS, Tsai CW, Wu CI, Lien CS, Liao WL, Ho CY, Bau DT. Association of DNA double-strand break gene XRCC6 genotypes and lung cancer in Taiwan. Anticancer Res. 2012;32:1015–20.PubMed Hsia TC, Liu CJ, Chu CC, Hang LW, Chang WS, Tsai CW, Wu CI, Lien CS, Liao WL, Ho CY, Bau DT. Association of DNA double-strand break gene XRCC6 genotypes and lung cancer in Taiwan. Anticancer Res. 2012;32:1015–20.PubMed
14.
go back to reference Chang WS, Ke HL, Tsai CW, Lien CS, Liao WL, Lin HH, Lee MH, Wu HC, Chang CH, Chen CC, Lee HZ, Bau DT. The role of XRCC6 T-991C functional polymorphism in renal cell carcinoma. Anticancer Res. 2012;32:3855–60.PubMed Chang WS, Ke HL, Tsai CW, Lien CS, Liao WL, Lin HH, Lee MH, Wu HC, Chang CH, Chen CC, Lee HZ, Bau DT. The role of XRCC6 T-991C functional polymorphism in renal cell carcinoma. Anticancer Res. 2012;32:3855–60.PubMed
15.
go back to reference Hsu CM, Yang MD, Chang WS, Jeng LB, Lee MH, Lu MC, Chang SC, Tsai CW, Tsai Y, Tsai FJ, Bau DT. The contribution of XRCC6/Ku70 to hepatocellular carcinoma in Taiwan. Anticancer Res. 2013;33:529–35.PubMed Hsu CM, Yang MD, Chang WS, Jeng LB, Lee MH, Lu MC, Chang SC, Tsai CW, Tsai Y, Tsai FJ, Bau DT. The contribution of XRCC6/Ku70 to hepatocellular carcinoma in Taiwan. Anticancer Res. 2013;33:529–35.PubMed
16.
go back to reference Mohamadynejad P, Saadat M. Genetic polymorphisms of XRCC1 (at codons 194 and 399) in Shiraz population (Fars province, southern Iran). Mol Biol Rep. 2008;35:669–72.PubMedCrossRef Mohamadynejad P, Saadat M. Genetic polymorphisms of XRCC1 (at codons 194 and 399) in Shiraz population (Fars province, southern Iran). Mol Biol Rep. 2008;35:669–72.PubMedCrossRef
17.
go back to reference Rafiee L, Saadat I, Saadat M. Glutathione S-transferase genetic polymorphisms (GSTM1, GSTT1 and GSTO2) in three Iranian populations. Mol Biol Rep. 2010;37:155–8.PubMedCrossRef Rafiee L, Saadat I, Saadat M. Glutathione S-transferase genetic polymorphisms (GSTM1, GSTT1 and GSTO2) in three Iranian populations. Mol Biol Rep. 2010;37:155–8.PubMedCrossRef
18.
go back to reference Rajaei M, Saadat I, Saadat M. High resolution melting analysis for detection of variable number of tandem repeats polymorphism of XRCC5. Biochem Biophys Res Commun. 2012;425:398–400.PubMedCrossRef Rajaei M, Saadat I, Saadat M. High resolution melting analysis for detection of variable number of tandem repeats polymorphism of XRCC5. Biochem Biophys Res Commun. 2012;425:398–400.PubMedCrossRef
19.
go back to reference Tsai YY, Bau DT, Chiang CC, Cheng YW, Tseng SH, Tsai FJ. Pterygium and genetic polymorphism of DNA double strand break repair gene Ku70. Molecular Vis. 2007;13:1436–40. Tsai YY, Bau DT, Chiang CC, Cheng YW, Tseng SH, Tsai FJ. Pterygium and genetic polymorphism of DNA double strand break repair gene Ku70. Molecular Vis. 2007;13:1436–40.
20.
go back to reference Nakamura Y, Koyama K, Matsushima M. VNTR (variable number of tandem repeat) sequences as transcriptional, translational, or functional regulators. J Hum Genet. 1998;43:149–52.PubMedCrossRef Nakamura Y, Koyama K, Matsushima M. VNTR (variable number of tandem repeat) sequences as transcriptional, translational, or functional regulators. J Hum Genet. 1998;43:149–52.PubMedCrossRef
21.
go back to reference Pucci S, Mazzarelli P, Rabitti C, Giai M, Gallucci M, Flammia G, Alcini A, Altomare V, Fazio VM. Tumor specific modulation of KU70/80 DNA binding activity in breast and bladder human tumor biopsies. Oncogene. 2001;20:739–47.PubMedCrossRef Pucci S, Mazzarelli P, Rabitti C, Giai M, Gallucci M, Flammia G, Alcini A, Altomare V, Fazio VM. Tumor specific modulation of KU70/80 DNA binding activity in breast and bladder human tumor biopsies. Oncogene. 2001;20:739–47.PubMedCrossRef
22.
go back to reference Lim JW, Kim H, Kim KH. Expression of Ku70 and Ku80 mediated by NF-kappa B and cyclooxygenase-2 is related to proliferation of human gastric cancer cells. J Biol Chem. 2002;277:46093–100.PubMedCrossRef Lim JW, Kim H, Kim KH. Expression of Ku70 and Ku80 mediated by NF-kappa B and cyclooxygenase-2 is related to proliferation of human gastric cancer cells. J Biol Chem. 2002;277:46093–100.PubMedCrossRef
23.
go back to reference Hosoi Y, Watanabe T, Nakagawa K, Matsumoto Y, Enomoto A, Morita A, Nagawa H, Suzuki N. Up-regulation of DNA-dependent protein kinase activity and Sp1 in colorectal cancer. Int J Oncol. 2004;25:461–8.PubMed Hosoi Y, Watanabe T, Nakagawa K, Matsumoto Y, Enomoto A, Morita A, Nagawa H, Suzuki N. Up-regulation of DNA-dependent protein kinase activity and Sp1 in colorectal cancer. Int J Oncol. 2004;25:461–8.PubMed
24.
go back to reference Saadat M, Ansari-Lari M. Polymorphism of XRCC1 (at codon 399) and susceptibility to breast cancer, a meta-analysis of the literatures. Breast Cancer Res Treat. 2009;115:137–44.PubMedCrossRef Saadat M, Ansari-Lari M. Polymorphism of XRCC1 (at codon 399) and susceptibility to breast cancer, a meta-analysis of the literatures. Breast Cancer Res Treat. 2009;115:137–44.PubMedCrossRef
25.
go back to reference Saadat M. Haplotype analysis of XRCC1 (at codons 194 and 399) and susceptibility to breast cancer, a meta-analysis of the literatures. Breast Cancer Res Treat. 2010;124:785–91.PubMedCrossRef Saadat M. Haplotype analysis of XRCC1 (at codons 194 and 399) and susceptibility to breast cancer, a meta-analysis of the literatures. Breast Cancer Res Treat. 2010;124:785–91.PubMedCrossRef
Metadata
Title
Association between polymorphisms at promoters of XRCC5 and XRCC6 genes and risk of breast cancer
Authors
Mehrdad Rajaei
Iraj Saadat
Shahpour Omidvari
Mostafa Saadat
Publication date
01-04-2014
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2014
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0885-8

Other articles of this Issue 4/2014

Medical Oncology 4/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.